Bradley Kropp

Pharmaceutical Product Development LLC engages in the operation of a global contract research organization, which provides drug development, laboratory and lifecycle management services. It offers adaptive trial design, bio analytical lab, bio similar development, biostatistics, GMP lab, clinical supplies, trial monitoring, CMC regulatory, data management, dental pain clinic, real-world outcomes, site intelligence and activation, central lab, global regulatory affairs, IRT systems, late stage research, medical communications, device and diagnostics, medical writing, nonclinical development and regulatory consulting and intelligence, regulatory development, innovation and vaccine sciences. The company was founded by Fredric N. Eshelman in 1985 and is headquartered in Wilmington, NC.

Jumo Health, Inc. operates as a children’s health education company which produces health content for children and families. The firms products allow children, families, and caregivers to learn and better manage their condition through podcasts, videos, games, and more. The company was founded by Kim Chilman-Blair and Kate Hersov in 2009 and is headquartered in New York, NY.

Innocrin Pharmaceuticals Holdings LLC discovers and develops oral inhibitors for the treatment of Castration-Resistant Prostate Cancer (CRPC). The company is headquartered in Durham, NC.

Aton Pharma, Inc. develops therapeutics for cancer and other diseases. Its products include Edecrin, Sodium Edecrin, Cuprimine, Demser and Syprine. The company was founded by Michael G. Wells in 2001 and is headquartered in Lawrenceville, NJ.

The North Carolina Biotechnology Center provides research and education grants. Its services include financing, technology assessment, business planning, and marketing strategies implementation. The company was founded in 1984 and is headquartered in Research Triangle Park, NC.

Accelerator Services Corp (Accelerator Services) is a venture capital firm founded in 2003 by Carl Weissman and Rodney F. Burgar. The firm is headquartered in Seattle, Washington.

Meryx, Inc. operates as an immune-oncology company. It focuses on developing drugs that inhibit tumor growth and initiate anti-tumor immunity in a range of cancer, such as leukemia, lung cancer, and melanoma. The company was founded by Doug Graham, Shelley Earp, and Stephen Frye in 2007 and is headquartered in Chapel Hill, NC.

Eshelman Ventures LLC (Eshelman Ventures) is a venture capital firm founded in 2014 by Fredric N. Eshelman. The firm is headquartered in Wilmington, North Carolina.

Cellective BioTherapy, Inc. engages in the research and development of novel cellular and monoclonal antibody-based platforms for treating cancers, autoimmunity, and immunodeficiency. Its proprietary pipeline and technology platform focuses on the unique aspects of B cell biology that are involved in regulating a variety of autoimmune diseases and inflammatory immune responses. The company was founded by Thomas F. Tedder in 2015 and is headquartered in Durham, NC.

Incyclix Bio, Inc., formerly known as Arc Therapeutics, is a pharmaceutical company that focuses on developing small molecule inhibitors of cyclin-dependent kinases (CDKs) to treat advanced and resistant cancers. The company is based in Durham, NC. The company's team has unique insights into the biology and structure of CDKs, which will facilitate the rapid discovery and development of a novel, potent, and selective Cdk2 inhibitor. Incyclix Bio was founded by industry experts with robust drug design, discovery, and development experience, including Patrick Roberts, John Bisi, Fredric N. Eshelman, and Jay C. Strum. Patrick Roberts has been the CEO since incorporation.

Innocrin Pharmaceuticals, Inc. develops oral inhibitors for the treatment of castration-resistant prostate cancer. It develops small molecule CYP17 lyase-selective inhibitors to treat resistant hormonally-dependent breast and prostate cancers. The firm’s product under pipeline is VT-464, a dual mechanism lyase-selective CYP17 inhibitor and androgen receptor (AR) antagonist that disrupts the validated biochemical pathways required for prostate cancer growth androgen biosynthesis and AR transcriptional signaling. The company was founded in 2004 and is headquartered in Durham, NC.